Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Article Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Team
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

Autoantibodies: What's in Their Teeth?

Aleeza J. Roth and Ronald J. Falk
JASN October 2011, 22 (10) 1783-1784; DOI: https://doi.org/10.1681/ASN.2011080836
Aleeza J. Roth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald J. Falk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

Serologic identification of circulating autoantibodies has proven useful in the diagnosis of patients with autoimmune disorders. In vitro and in vivo1–5 observations suggest that some autoantibodies are more than just serologic markers; they also participate in the pathogenesis of disease. Shining examples of pathogenic autoantibodies are anti-glomerular basement membrane (anti-GBM) autoantibodies found in anti-GBM disease and the Goodpasture syndrome. In 1967, Lerner and colleagues transferred autoantibodies purified from sera of a patient with anti-GBM disease to recipient monkeys and induced glomerulonephritis.1 Nearly half a century of investigation has served to refine our understanding of these autoantibodies and the havoc they cause. Detection of anti-GBM autoantibodies in patients with glomerulonephritis prompts emergent therapy, and frequently patients on dialysis with persistent anti-GBM antibodies are not eligible for kidney transplantation until their autoantibody titers are reduced to near normal levels.

In this issue of JASN, Olson and colleagues6 present an intriguing observation of serologic detection of anti-GBM autoantibodies in ostensibly healthy individuals for months if not years before the onset of their anti-GBM disease. This observation is surprising, yet it should not be so, as circulating autoantibodies have been found in healthy individuals who eventually develop other autoimmune diseases. For example, 88% of SLE patients have autoantibodies to at least one autoantigen while clinically asymptomatic.7 These autoantibodies are detectable in multiple samplings for years before diagnosis. It appears that what tips the balance into the clinical presentation of lupus is accumulation of multiple diverse autoantibodies.7

The question that arises with the finding of Olson and colleagues is what triggers the crucial hit that pushes individuals into anti-GBM disease, when they have had years of health with circulating anti-GBM autoantibodies.6 Explanations to consider include that the reactive sites of these autoantibodies found before the onset of disease are restricted to regions of the α3(IV)NC1 domain of type IV collagen that are nonpathogenic, that is, they do not recognize crucial pathogenic epitopes; that the crucial pathogenic autoantibody is readily available but the target epitope on the autoantigen is hidden; or that these autoantibodies have nothing to do with the pathogenesis of disease. In the case of anti-GBM disease, this last possibility appears remote.

The presence of serologically detectable anti-GBM autoantibodies over years before disease onset compels one to consider what predisposed these individuals to develop disease. Were they naturally occurring autoantibodies, which are known to exist in a number of autoimmune diseases including anti-GBM antibody disease8 and ANCA vasculitis?9 Characteristically, these antibodies have low affinity and avidity for their target antigens and thus are less likely to be pathogenic.

The benign nature of naturally occurring autoantibodies makes it more likely that the anti-GBM autoantibodies observed by Olsen and colleagues6 represent either pathogenic or nonpathogenic autoantibodies, considering that all of the patients in the study eventually developed clinical disease. If these were nonpathogenic, it is possible these autoantibodies were present in the absence of a clinical phenotype because none reacted with a critical epitope required for disease. The pre-existing autoantibodies were lying-in-wait for that final trigger: a response to a molecular mimic or exposure to a complementary protein structure that triggers production of the crucial pathogenic autoantibodies10,11 or an alteration in the collagen microenvironment.12 Fine mapping of epitope specificity would help clarify whether this is the case, but to date, anti-α3(IV)NC1 autoantibodies identified in healthy humans have not been studied in this detail.8

A second and more probable possibility is that pathogenic autoantibodies are available for months to years before disease but their target epitope is concealed. Pedchenko and colleagues have demonstrated the conformational nature of collagen molecules in the glomerular basement membrane during active anti-GBM disease.13 Somehow, a conformation-dependent disease-related epitope is exposed by disassociation of the endogenous hexamer structure of the α3 chain of type IV collagen.13 The cause of disruption in the hexamer structure is unknown. Do naturally occurring autoantibodies contribute to disruption, or is it due to posttranslational changes, proteolytic cleavage by exogenous environmental factors, or is it a combination of events? Conceivably, asymptomatic autoantibodies reactive to one part of a target antigen could reveal or disrupt autoantigen conformation to expose a cryptic epitope.

Recently, a mechanism underpinning display of critical autoantigens was described that brought into play alterations in epigenetic regulation of the ANCA antigen proteinase 3 (PR3) and myeloperoxidase (MPO) genes.14 The loss of epigenetic control of these potential antigens results in transcription, likely leading to production of excessive and perhaps aberrant protein. This begs the question of whether changes in these antigens provide a path for production of naturally occurring antibodies that sets the stage for later onset of disease and moreover, whether this is a direct path for generation of the crucial pathogenic antibodies. To take this one step further, is the relapse and remission phenotype of many autoimmune diseases a consequence of changes in antigen integrity or antigen availability?

The relative rarity of the autoimmune disease most assuredly requires more than a one-hit and probably more than a two-hit phenomena to incite disease. Multiple hits must be required, including a susceptible genetic background (especially HLA genes)15 and disregulated T and B cells.16–18 Yet the present study, as well as those akin to it, provides critical insights into patient management and eventual novel approaches to treatment. Modern immunosuppressive therapy is aimed at damping down the immune system with drugs including glucocorticoids and alkylating agents or at targeting B cells (rituximab). Perhaps future directions should target understanding the factors that open or close conformational antigens or activate or silence genes that transcribe them. Are the real culprits environmental factors including microbes or toxins that alter antigens and the antibody response to them? In autoantibody diseases, we must consider not only the autoantibody but also the autoantigen to which they are binding.

DISCLOSURES

None.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “Asymptomatic Autoantibodies Associate with Future Anti-glomerular Basement Membrane Disease,” on pages 1946–1952.

  • Copyright © 2011 by the American Society of Nephrology

REFERENCES

  1. 1.↵
    1. Lerner RA,
    2. Glassock RJ,
    3. Dixon FJ
    : The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med 126: 989–1004, 1967
    OpenUrlAbstract
  2. 2.↵
    1. Wilson CB,
    2. Dixon FJ
    : Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 3: 74–89, 1973
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Bansal PJ,
    2. Tobin MC
    : Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 93: 398–401, 2004
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Falk RJ,
    2. Terrell RS,
    3. Charles LA,
    4. Jennette JC
    : Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 87: 4115–4119, 1990
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Xiao H,
    2. Heeringa P,
    3. Hu P,
    4. Liu Z,
    5. Zhao M,
    6. Aratani Y,
    7. Maeda N,
    8. Falk RJ,
    9. Jennette JC
    : Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955–963, 2002
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Olson SW,
    2. Arbogast CB,
    3. Baker TP,
    4. Owshalimpur D,
    5. Oliver DK,
    6. Abbott KC,
    7. Yuan CM
    : Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 22: 1946–1952, 2011
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Arbuckle MR,
    2. McClain MT,
    3. Rubertone MV,
    4. Scofield RH,
    5. Dennis GJ,
    6. James JA,
    7. Harley JB
    : Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349: 1526–1533, 2003
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Yang R,
    2. Cui Z,
    3. Hellmark T,
    4. Segelmark M,
    5. Zhao MH,
    6. Wang HY
    : Natural anti-GBM antibodies from normal human sera recognize alpha3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. Clin Immunol 124: 207–212, 2007
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Cui Z,
    2. Zhao MH,
    3. Segelmark M,
    4. Hellmark T
    : Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 78: 590–597, 2010
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Kohm AP,
    2. Fuller KG,
    3. Miller SD
    : Mimicking the way to autoimmunity: An evolving theory of sequence and structural homology. Trends Microbiol 11: 101–105, 2003
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Pendergraft WF 3rd.,
    2. Preston GA,
    3. Shah RR,
    4. Tropsha A,
    5. Carter CW Jr.,
    6. Jennette JC,
    7. Falk RJ
    : Autoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3. Nat Med 10: 72–79, 2004
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Hamano Y,
    2. Okude T,
    3. Shirai R,
    4. Sato I,
    5. Kimura R,
    6. Ogawa M,
    7. Ueda Y,
    8. Yokosuka O,
    9. Kalluri R,
    10. Ueda S
    : Lack of collagen XVIII/endostatin exacerbates immune-mediated glomerulonephritis. J Am Soc Nephrol 21: 1445–1455, 2010
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Pedchenko V,
    2. Bondar O,
    3. Fogo AB,
    4. Vanacore R,
    5. Voziyan P,
    6. Kitching AR,
    7. Wieslander J,
    8. Kashtan C,
    9. Borza DB,
    10. Neilson EG,
    11. Wilson CB,
    12. Hudson BG
    : Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363: 343–354, 2010
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Ciavatta DJ,
    2. Yang J,
    3. Preston GA,
    4. Badhwar AK,
    5. Xiao H,
    6. Hewins P,
    7. Nester CM,
    8. Pendergraft WF 3rd.,
    9. Magnuson TR,
    10. Jennette JC,
    11. Falk RJ
    : Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 120: 3209–3219, 2010
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Hudson BG,
    2. Tryggvason K,
    3. Sundaramoorthy M,
    4. Neilson EG
    : Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348: 2543–2556, 2003
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Ooi JD,
    2. Phoon RK,
    3. Holdsworth SR,
    4. Kitching AR
    : IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol 20: 980–989, 2009
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Mesnard L,
    2. Keller AC,
    3. Michel ML,
    4. Vandermeersch S,
    5. Rafat C,
    6. Letavernier E,
    7. Tillet Y,
    8. Rondeau E,
    9. Leite-de-Moraes MC
    : Invariant natural killer T cells and TGF-beta attenuate anti-GBM glomerulonephritis. J Am Soc Nephrol 20: 1282–1292, 2009
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Robertson J,
    2. Wu J,
    3. Arends J,
    4. Zhou C,
    5. McMahon J,
    6. Torres L,
    7. Lou YH
    : Activation of glomerular basement membrane-specific B cells in the renal draining lymph node after T cell-mediated glomerular injury. J Am Soc Nephrol 16: 3256–3263, 2005
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 22 (10)
Journal of the American Society of Nephrology
Vol. 22, Issue 10
1 Oct 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Autoantibodies: What's in Their Teeth?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Autoantibodies: What's in Their Teeth?
Aleeza J. Roth, Ronald J. Falk
JASN Oct 2011, 22 (10) 1783-1784; DOI: 10.1681/ASN.2011080836

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Autoantibodies: What's in Their Teeth?
Aleeza J. Roth, Ronald J. Falk
JASN Oct 2011, 22 (10) 1783-1784; DOI: 10.1681/ASN.2011080836
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • DISCLOSURES
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury
  • Missing Self and DSA—Synergy of Two NK Cell Activation Pathways in Kidney Transplantation
  • The Road Ahead for Research on Air Pollution and Kidney Disease
Show more Up Front Matters

Editorials

  • In Search of the Optimal Target for Phosphate Control: Episode 1
  • Promoting Equity in Eligibility for Registration on the Kidney Transplantation Waiting List: Looking beyond eGFRcr
  • Glomerular Exostosin Deposits in Membranous Lupus Nephritis—a Dialogue
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Asymptomatic Autoantibodies Associate with Future Anti-glomerular Basement Membrane Disease
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire